metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.
Products, services, technology
Best-in-class chelating agent for Wilson Disease (primary): Preclinical
Best-in-class chelating agent for lead poisoning (on hold): Preclinical
Additional indications: Menkes Disease, NBIA Disorders, Cobalturia
Cooperation possibilities
As a drug development startup, metaLead aims to fundraise from venture capitals and family offices, amongst others, until superior safety and efficacy are verified in humans. Afterward, we aim to pursue an M&A or out license to pharmaceutical organizations that can bring the technologies to market.
- http://metalead.ch
- +41 76 779 82 23
- michal@metalead.ch
- Michal Shoshan
Some insights
Starting with Wilson disease, metaLead aims to improve patient health and treatment adherence with a once-daily oral adminstration, thus positively affecting their productivity and quality of life, while also reducing healthcare costs due to fewer side effects and hospitalizations.
We are proud of our unique, best-in-class, and innovative technology. We are especially proud of the positive impact we can have on patients, their caregivers, and healthcare systems globally, improving their quality of life and health due to the superior efficacy and safety profile we aim for.
Daniela Marino, CEO of Cutiss AG, is a key role model for me. I admire her ambition to pioneer skin therapy solutions. Not only is Cutiss' tissue therapy product unique and inspiring, but as a CEO, she is charismatic and has a vibrant personality that stands out.
In addition to commitment and work ethic, our team is incredibly diverse, both educationally and culturally. Our team members are from multiple continents, with educational backgrounds in inorganic chemistry, biology, business development, and finance. Our next hire is a COO with clinical expertise.
My son (10 years old) knows that metaLead is developing drugs, and despite the long time to market, he keeps asking when he will see our technology at the nearest pharmacy.
metaLead can benefit significantly from expanding its network in the Swiss biotech ecosystem, learning from serial entrepreneurs' experience, finding new talent to join the team, for investment in future financing rounds, and for future M&A opportunities.
Early stage life science investors
Serial entrepreneurs open to share their experience
Talented individuals motivated to become metaLead's new COO, with clinical drug development and management experience
Pharma companies interested in M&A or outlicensing metaLead's technology in the future